PerQseal® Elite Venous Clinical Study (ELITE-Venous)

Recruiting now · Not applicable

Conditions studied: Large Hole Percutaneous Venous Closure

In brief

The objective of this study is to evaluate the safety and effectiveness of the PerQseal Elite vascular closure system when used to achieve haemostasis of common femoral venotomies created by 14 to 22F sheaths (venotomy up to 26F) in patients undergoing percutaneous catheter-based interventional procedures, with sufficient rigor to provide robust scientific evidence for the demonstration of clinical safety and efficacy of the PerQseal Elite closure system to support a CE-mark and a PMA submission.

Key facts

Study ID: NCT06007339
Run by: Vivasure Medical Limited
People needed: 90
Starts: 2024-04-01
Expected to finish: 2025-12-01
Last updated by the study team: 2025-03-26

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Age ≥ 19 years.
Clinically indicated for a percutaneous venous interventional catheter-based procedure, e.g., mitral valve edge to edge repair, left atrial appendage device closure, leadless pacemaker implantation, patent foramen ovale closure or use of a circulatory assist device or extracorporeal oxygenation using a common femoral venotomy created by a 14 to 22F sheath (venotomy up to 26F).
Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.
Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.
Baseline Exclusion Criteria:
Evidence of current systemic bacterial or cutaneous infection, including groin infection,
Known bleeding diathesis, unstable INR, definite or potential coagulopathy, platelet count < 100,000/μl or subjects on long term anticoagulants with an INR > 2.2 within 12 hours prior to index procedure,
Significant anaemia (example: haemoglobin < 8 g/dL or haematocrit < 22%), within 24 hours prior to index procedure,
Known type II heparin-induced thrombocytopenia,
Documented right ventricular dysfunction < 13%,
Ipsilateral or contralateral lower extremity amputation,
Previous groin surgery within the region of the ipsilateral vessel access,
Common femoral vein diameter stenosis > 50% or previous bypass surgery/stent placement in the common femoral vein of target leg,
Known existing nerve damage in the target leg,
Nephrotic syndrome or renal insufficiency (Glomerular Filtration Rate ≤ 30 ml/min or baseline serum creatinine > 2.5 mg/dl) or on renal replacement therapy or albumin level < 3.5 g/dl or symptoms of pitting oedema,
Systolic pulmonary artery pressure > 60 mmHg
Known allergy to any of the materials used in the PerQseal Elite device (refer to Investigator's Brochure),
Subject is unsuitable for surgical repair of the target leg access site,
Subject has undergone a percutaneous procedure greater than 8F sheath in the target vessel, within the 90-days prior to index procedure,
Subject has undergone a percutaneous procedure of 8F sheath or less using an absorbable intravascular closure device for haemostasis, in the target vessel, within the 90-days prior to index procedure,
Subject has undergone a percutaneous procedure of 8F sheath or less using a suture mediated closure device or manual/mechanical pressure for haemostasis in the target vessel, within the 30-days prior to index procedure,
History of DVT or pulmonary embolism or venous thrombotic event,
Splenectomy or suffering psoriasis or paraesthesia of the ipsilateral leg,
Further planned endovascular/catheter-based procedure in the target leg in the 30-days following the index procedure,
Subject is enrolled in another investigational medical device or drug study,

Where it is running

Erasmus UMC — Rotterdam, Rotterdam, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.